President Trump's FDA Nominee, Dr. Heidi Overton, Expected to Renew Scrutiny on Abortion Drug Mifepristone
President Trump's nominee for FDA Commissioner, Dr. Heidi Overton, is expected to bring renewed scrutiny to mifepristone, the abortion drug currently undergoing a federal safety review. John Mize, CEO of Americans United for Life (AUL), a pro-life organization, stated that Overton, known for her pro-life views and experience in government and medical research, is the 'right candidate' to lead the FDA. Mize believes Overton will objectively evaluate mifepristone, which carries an FDA boxed warning for serious risks, and potentially tighten regulations. The FDA previously relaxed in-person dispensing requirements for mifepristone in 2021 and later removed them permanently. Overton has publicly criticized the expansion of access to abortion pills, accusing the Biden administration of wrongly justifying mail-order access during the COVID-19 pandemic.